Press Releases Details

Home  >  Investors & News  >  Press Releases  >  Press Releases Details
View all news

Momenta Pharmaceuticals Appoints Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer


CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer and Senior Vice President, Development.

"Santiago's deep understanding of successful clinical development coupled with his experience as a principal investigator on many trials, will be a huge asset to our expanding pipeline of biosimilars and novel drugs for autoimmune diseases. I am delighted to welcome him to our team," said Craig A. Wheeler, President and Chief Executive Officer of Momenta Pharmaceuticals.

Dr. Arroyo joins Momenta from Boston Pharmaceuticals, where he was Chief Medical Officer. Previously he was Senior Vice President, Head of Clinical Research and Chief Medical Officer of Biotherapeutics and Pharmatherapeutics at Pfizer Inc. in the areas of Cardiovascular and Metabolism, Pain, Neuroscience, Regenerative Medicine and Rare Diseases. He was previously Therapeutic Area Head for Neurosciences, Discovery Medicine and Clinical Pharmacology at Bristol-Myers Squibb and Neurology Global Therapeutic Area Head for Eisai Global Clinical Development. Dr. Arroyo was an Instructor in Neurology at the Johns Hopkins Hospital and helped set up and run the epilepsy programs at the Medical College of Wisconsin and Hospital Clinic of Barcelona, Spain. Dr. Arroyo received his medical degree from the Autonomous University of Madrid and his Ph.D. from the University of Barcelona, Spain.

"This is an exciting time at Momenta as the pipeline is both growing and advancing rapidly. We expect multiple data readouts across the biosimilar and novel programs this year," said Dr. Arroyo. "Momenta's understanding of innovative science and efficient clinical development is extremely compelling and I look forward to contributing to the development of products that will change the lives of patients."

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for autoimmune indications.

To receive additional information about Momenta, please visit the website at, which does not form a part of this press release.

The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward-Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements regarding the Company's pipeline; Dr. Arroyo's expected impact on the Company's pipeline; and the timing of clinical trial results.  Forward-looking statements may be identified by words such as "believe," "continue," "could," "expect," "guidance," "may," "plan," "potential," "target," "will" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the year ended March 31, 2017, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


Sarah CarmodyMomenta Pharmaceuticals



Karen SharmaMacDougall Biomedical Communications


Primary Logo

Momenta Pharmaceuticals, Inc.

News Provided by Acquire Media

Multimedia Files:

View all news